Clinical Trial Search

Primary: Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin…

Primary: Mean Pain Bowel Symptom Scale (BSS) Score Over Last 4 Weeks of Study (Weeks 9-12) — 25.3; 42.0 units on a scale — p=0.008

Primary: Ocular Inflammation — 21; 24; 18; 8 participants

Primary: Progression Free Survival (PFS) — 8.6 Months

Primary: Objective Response Rate (ORR) — 16 percentage of participants

Primary: Response Rate (RR) — 6 percentage of participants

Primary: Percentage of Subjects With Disease Activity Free Status up to Week 48 — 37.2; 35.3 percentage of subjects

Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…

Primary: Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours) — 6.92; 6.51 log-transformed total cough count

Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12…

Primary: Adjusted Annualized Relapse Rate Between Baseline and Week 52 — 0.458; 0.211; 0.230 relapses per person-years — p=<0.0001

Primary: Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4]) — 45.4; 58.3; 56.5; 59.8 percentage of participants — p=0.057

Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea

Primary: Tumor Response Rate to LBH589. — 13; 0 participants

Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70